Session

GU cancer in the elderly (>Age 75)

Meeting of the EAU Section of Oncological Urology (ESOU) in cooperation with the European Organisation for Research and Treatment of Cancer Genito-Urinary Cancer Group (EORTC GUCG), The European Uro-Oncology Group (EUOG), The European Society of Surgical Oncology (ESSO) and the European Society for Radiotherapy & Oncology (ESTRO)

  • Location:
    Room 14b (ICM, Level 1)
  • Chairs:
     M. Brausi, Modena (IT)
     G.N. Thalmann, Bern (CH)
  • Aims and objectives of this session

    In this Joint Meeting of EUOG, ESSO, ESOU, ESSO, ESTRO and EORTC would like to adress relevant issues in GU cancer managment. The EUOG will focus on the potential of markers in clinical decision making. The ESSO will adress the issue of preoperative planning in pelvic surgery. The ESOU raises the important issue and increasing problem of how to manage the elderly patient with GU cancers. The objectives of this meeting are to provide Information on who needs therapy, who may not need treatment and who might be a candidate for minimal invasive and alternative treatment modalities. ESTRO will provide Information on the role of adjuvant hormonal treatment in the context of salvage radiotherapy. Finally the EORTC will discuss how new studies for the Management of testicular cancer should be designed.

The European Uro-Oncology Group (EUOG)
 
Moderator:
 S. Osanto, Leiden (NL)
Molecular tumour boards: Molecular diagnostic in clinical practice
 J.A. Schalken, Nijmegen (NL)
Discussion
The European Society of Surgical Oncology (ESSO)
3rd evaluation before planning pelvic oncological surgery
 P. Tekkis, London (GB)
Discussion
Meeting of the EAU Section of Oncological Urology (ESOU)
Welcome and introduction
 M. Brausi, Modena (IT)
Evaluating the elderly and frail patients
 A. Hohn, Köln (DE)
Prostate cancer in the elderly
Who is the appropriate candidate for definitive therapy?
 S. Joniau, Leuven (BE)
Alternative treatments: Are they more appropriate?
 M. Emberton, London (GB)
Debate: Radical cystectomy in muscle invasive TCC of the bladder
Pro: It should be performed more often
 A. Stenzl, Tübingen (DE)
Con: Bladder sparing surgery with trimodality treatment is the new avenue
 R.A. Huddart, Sutton (GB)
Discussion
Debate Localised renal cancer in the elderly
Yes: Surgery is preferable
 O. Rodriguez Faba, Barcelona (ES)
Alternative treatments are the standard
 J.J.M.C.H. De La Rosette, Amsterdam (NL)
Expectant management is a good option
 A. Volpe, Torino (IT)
Discussion
Complications of uro-onco surgery: How to avoid them
Prostate
 C. Surcel, Bucharest (RO)
Bladder
 E. Xylinas, Paris (FR)
Kidney
 S.D. Brookman-May, Munich (DE)
Discussion
The European SocieTy for Radiotherapy & Oncology (ESTRO)
Role of adjuvant hormonal treatment together with salvage radiation therapy for local recurrence after prostatectomy
 P. Pommier, Lyon (FR)
Discussion
The European Organisation for Research and Treatment of Cancer Genito-Urinary Cancer Group (EORTC GUCG)
Designing the next generation of studies in germ cell cancers
 S. Gillessen, St. Gallen (CH)
Discussion
Summary and closure
 
 M. Brausi, Modena (IT)